Philippe MenaschÃ©

List of Publications by Year
in descending order

84 papers	8,521 citations	94433 37 h-index	71685 76 g-index
87 all docs	87 docs citations	87 times ranked	7683 citing authors

#	Article	IF	Citations
1	Methods for the identification and characterization of extracellular vesicles in cardiovascular studies: from exosomes to microvesicles. Cardiovascular Research, 2023, 119, 45-63.	3.8	44
2	Dynamic contrast enhanced â€" MRI efficiency in detecting embolization-induced perfusion defects in a rabbit model of critical-limb-ischemia. Magnetic Resonance Imaging, 2022, 87, 88-96.	1.8	0
3	Extracellular vesicles from human cardiovascular progenitors trigger a reparative immune response in infarcted hearts. Cardiovascular Research, 2021, 117, 292-307.	3.8	57
4	Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine. Cardiovascular Research, 2021, 117, 1428-1433.	3.8	20
5	Extracellular Vesicles and Biomaterial Design: New Therapies for Cardiac Repair. Trends in Molecular Medicine, 2021, 27, 231-247.	6.7	31
6	Extracellular vesicles can be processed by electrospinning without loss of structure or function. Materials Letters, 2021, 282, 128671.	2.6	7
7	Editorial: Bioengineering and Biotechnology Approaches in Cardiovascular Sciences. Frontiers in Bioengineering and Biotechnology, 2021, 9, 746435.	4.1	0
8	Development of extracellular vesicle-based medicinal products: A position paper of the group â€œExtracellular Vesicle translatiOn to clinicaL perspectiVEs â€" EVOLVE Franceâ€. Advanced Drug Delivery Reviews, 2021, 179, 114001.	13.7	42
9	Extracellular vesicles fail to trigger the generation of new cardiomyocytes in chronically infarcted hearts. Theranostics, 2021, 11, 10114-10124.	10.0	10
10	Basic and Translational Research in Cardiac Repair and Regeneration. Journal of the American College of Cardiology, 2021, 78, 2092-2105.	2.8	42
11	In vitro controlled release of extracellular vesicles for cardiac repair from poly(glycerol sebacate) acrylate-based polymers. Acta Biomaterialia, 2020, 115, 92-103.	8.3	18
12	Cell Therapy With Human ESC-Derived Cardiac Cells: Clinical Perspectives. Frontiers in Bioengineering and Biotechnology, 2020, 8, 601560.	4.1	9
13	Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine. Science Translational Medicine, 2020, 12, .	12.4	112
14	CHIR99021 and fibroblast growth factor 1 enhance the regenerative potency of human cardiac muscle patch after myocardial infarction in mice. Journal of Molecular and Cellular Cardiology, 2020, 141, 1-10.	1.9	40
15	Cardiac cell therapy: Current status, challenges and perspectives. Archives of Cardiovascular Diseases, 2020, 113, 285-292.	1.6	18
16	Attrition of the cardiothoracic surgeon-scientist: Definition of the problem and remedial strategies. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 504-508.	0.8	18
17	Transatlantic Editorial: Attrition of the Cardiothoracic Surgeon-Scientist: Definition ofÂtheÂProblem and Remedial Strategies. Annals of Thoracic Surgery, 2019, 108, 315-318.	1.3	6
18	Clinical Translation of Pluripotent Stem Cell Therapies: Challenges and Considerations. Cell Stem Cell, 2019, 25, 594-606.	11.1	53

#	Article	IF	Citations
19	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. Cardiovascular Research, 2019, 115, 488-500.	3.8	90
20	Ten-year follow-up of unreplaced Valsalva sinuses after aortic valve replacement in bicuspid aortic valve disease. Archives of Cardiovascular Diseases, 2019, 112, 305-313.	1.6	4
21	Stem cellâ€"derived exosomes and the failing heart: Small cause, big effect. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1089-1092.	0.8	7
22	Transplantation of Human Embryonic StemÂCellâ€"Derived Cardiovascular Progenitors for SevereÂIschemic LeftÂVentricular Dysfunction. Journal of the American College of Cardiology, 2018, 71, 429-438.	2.8	336
23	Acellular therapeutic approach for heart failure: inÂvitro production of extracellular vesicles from human cardiovascular progenitors. European Heart Journal, 2018, 39, 1835-1847.	2.2	137
24	Will cardiac surgeons even turn pumpkins into carriages?. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1647-1649.	0.8	0
25	Multiple reoperations on the aortic valve: outcomes and implications for future potential valve-in-valve strategyâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 1251-1257.	1.4	8
26	Platelet vesicles help cardiac stem cells engraft. Nature Biomedical Engineering, 2018, 2, 4-5.	22.5	0
27	Intra-Cardiac Release of Extracellular Vesicles Shapes Inflammation Following Myocardial Infarction. Circulation Research, 2018, 123, 100-106.	4.5	181
28	Evaluation of a new model of hind limb ischemia in rabbits. Journal of Vascular Surgery, 2018, 68, 849-857.	1.1	5
29	Thermoresponsive Gel Embedded with Adipose Stem-Cell-Derived Extracellular Vesicles Promotes Esophageal Fistula Healing in a Thermo-Actuated Delivery Strategy. ACS Nano, 2018, 12, 9800-9814.	14.6	60
30	Long-Term Engraftment (16 Years) of Myoblasts in a Human Infarcted Heart. Stem Cells Translational Medicine, 2018, 7, 705-708.	3.3	9
31	Experimental Evaluation of Endovascular Fenestration Scissors in an Ovine Model of Aortic Dissection. European Journal of Vascular and Endovascular Surgery, 2018, 56, 373-380.	1.5	3
32	Cell therapy trials for heart regeneration â€" lessons learned and future directions. Nature Reviews Cardiology, 2018, 15, 659-671.	13.7	200
33	VÃ©sicules extra cellulaires : nouveaux agents thÃ©rapeutiques pour la rÃ©paration cardiaque ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 755-769.	0.0	0
34	HEMO₂life as a protective additive to Celsior solution for static storage of donor hearts prior to transplantation. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 717-722.	2.8	27
35	A 3D magnetic tissue stretcher for remote mechanical control of embryonic stem cell differentiation. Nature Communications, 2017, 8, 400.	12.8	123
36	Do not throw the baby with the water bath!. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 557.	0.8	0

#	Article	IF	Citations
37	Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass. JAMA - Journal of the American Medical Association, 2017, 318, 548.	7.4	143
38	Building a bioartificial heart: A 3-song saga. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 744-747.	0.8	0
39	Fibers for hearts: A critical review on electrospinning for cardiac tissue engineering. Acta Biomaterialia, 2017, 48, 20-40.	8.3	230
40	Global position paper on cardiovascular regenerative medicine. European Heart Journal, 2017, 38, 2532-2546.	2.2	133
41	The future of stem cells: Should we keep the â€œstemâ€•and skip the â€œcellsâ€?. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 345-349.	0.8	8
42	CD133+ cells: How could they have an IMPACT?. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1589-1591.	0.8	2
43	Rationale and design of the multicenter randomized trial investigating the effects of levosimendan pretreatment in patients with low ejection fraction (â‰¤40 %) undergoing CABG with cardiopulmonary bypass (LICORN study). Journal of Cardiothoracic Surgery, 2016, 11, 127.	1.1	12
44	Mast cells regulate myofilament calcium sensitization and heart function after myocardial infarction. Journal of Experimental Medicine, 2016, 213, 1353-1374.	8.5	97
45	Cardiovascular progenitorâ€“derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure. Journal of Heart and Lung Transplantation, 2016, 35, 795-807.	0.6	161
46	Nanofibrous clinical-grade collagen scaffolds seeded with human cardiomyocytes induces cardiac remodeling in dilated cardiomyopathy. Biomaterials, 2016, 80, 157-168.	11.4	65
47	Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. European Journal of Cardio-thoracic Surgery, 2016, 49, 682-689.	1.4	11
48	Comparative Analysis of Methods to Induce Myocardial Infarction in a Closed-Chest Rabbit Model. BioMed Research International, 2015, 2015, 1-9.	1.9	9
49	Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report: Figure 1. European Heart Journal, 2015, 36, 2011-2017.	2.2	383
50	The Evolution of the Stem Cell Theory for Heart Failure. EBioMedicine, 2015, 2, 1871-1879.	6.1	24
51	Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold. Journal of Heart and Lung Transplantation, 2015, 34, 1198-1207.	0.6	80
52	Fabrication of cardiac patch by using electrospun collagen fibers. Microelectronic Engineering, 2015, 144, 46-50.	2.4	37
53	Polymer-Based Reconstruction of the Inferior Vena Cava in Rat: Stem Cells or RGD Peptide?. Tissue Engineering - Part A, 2015, 21, 1552-1564.	3.1	21
54	Stem cells in the management of advanced heart failure. Current Opinion in Cardiology, 2015, 30, 179-185.	1.8	9

#	Article	IF	Citations
55	Stem cells for the treatment of heart failure. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140373.	4.0	6
56	Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. European Heart Journal, 2015, 36, 743-750.	2.2	137
57	Effect of severe acidosis on vasoactive effects of epinephrine and norepinephrine in human distal mammary artery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1698-1705.	0.8	7
58	How Close Are We to Using Stem Cells in Routine Cardiac Therapy?. Canadian Journal of Cardiology, 2014, 30, 1265-1269.	1.7	2
59	Editorial Comment: Adenosine in heart transplants: have we finally found the good indication?. European Journal of Cardio-thoracic Surgery, 2013, 43, 1209-1210.	1.4	0
60	Can Magnetic Targeting of Magnetically Labeled Circulating Cells Optimize Intramyocardial Cell Retention?. Cell Transplantation, 2012, 21, 679-691.	2.5	41
61	Stem cell therapy for chronic heart failure. Lessons from a 15-year experience. Comptes Rendus - Biologies, 2011, 334, 489-496.	0.2	19
62	Cardiac cell therapy: Lessons from clinical trials. Journal of Molecular and Cellular Cardiology, 2011, 50, 258-265.	1.9	153
63	Recommendations for Successful Training on Methods of Delivery of Biologics for Cardiac Regeneration. JACC: Cardiovascular Interventions, 2010, 3, 265-275.	2.9	71
64	A polydioxanone electrospun valved patch to replace the right ventricular outflow tract in a growing lamb model. Biomaterials, 2010, 31, 4056-4063.	11.4	50
65	A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. Journal of Clinical Investigation, 2010, 120, 1125-1139.	8.2	287
66	Cell therapy for peripheral arterial disease. Current Opinion in Molecular Therapeutics, 2010, 12, 538-45.	2.8	10
67	Stem Cell Therapy for Heart Failure. Circulation, 2009, 119, 2735-2740.	1.6	122
68	Cell Delivery: Intramyocardial Injections or Epicardial Deposition? A Head-to-Head Comparison. Annals of Thoracic Surgery, 2009, 87, 1196-1203.	1.3	112
69	Cell-based Therapy for Heart Disease: A Clinically Oriented Perspective. Molecular Therapy, 2009, 17, 758-766.	8.2	63
70	Cardiac Cell Therapy Trials: Chronic Myocardial Infarction and Congestive Heart Failure. Journal of Cardiovascular Translational Research, 2008, 1, 201-206.	2.4	10
71	Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. European Journal of Heart Failure, 2008, 10, 1065-1072.	7.1	119
72	The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial. Circulation, 2008, 117, 1189-1200.	1.6	878

#	Article	IF	Citations
73	Current Status and Future Prospects for Cell Transplantation to Prevent Congestive Heart Failure. Seminars in Thoracic and Cardiovascular Surgery, 2008, 20, 131-137.	0.6	43
74	Skeletal Myoblasts Preserve Remote Matrix Architecture and Global Function When Implanted Early or Late After Coronary Ligation Into Infarcted or Remote Myocardium. Circulation, 2008, 118, S130-S137.	1.6	57
75	Challenging the Cardiac Differentiation of Bone Marrow Cells: A Clinical Perspective. Molecular Therapy, 2008, 16, 1000-1001.	8.2	6
76	Skeletal Myoblast Transplantation for Ischemic Heart Failure. , 2008, , 189-202.		0
77	Cellular Therapy in Thoracic and Cardiovascular Disease. Annals of Thoracic Surgery, 2007, 84, 339-342.	1.3	2
78	Skeletal Myoblasts as a Therapeutic Agent. Progress in Cardiovascular Diseases, 2007, 50, 7-17.	3.1	129
79	Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. Journal of the American College of Cardiology, 2003, 41, 1078-1083.	2.8	1,072
80	Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet, The, 2003, 361, 491-492.	13.7	265
81	Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7808-7811.	7.1	466
82	Cell transplantation for the treatment of heart failure. Seminars in Thoracic and Cardiovascular Surgery, 2002, 14, 157-166.	0.6	38
83	Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation, 2002, 106, I131-6.	1.6	144
84	Myoblast transplantation for heart failure. Lancet, The, 2001, 357, 279-280.	13.7	1,044